Journal article

Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer

Aesha I Ali, Amanda J Oliver, Tinaz Samiei, Jack D Chan, Michael H Kershaw, Clare Y Slaney

FRONTIERS IN ONCOLOGY | FRONTIERS MEDIA SA | Published : 2019

Abstract

Conventional treatments for pancreatic cancer are largely ineffective, and the prognosis for the vast majority of patients is poor. Clearly, new treatment options are desperately needed. Immunotherapy offers hope for the development of treatments for pancreatic cancer. A central requirement for the efficacy of this approach is the existence of cancer antigen-specific T cells, but these are often not present or difficult to isolate for most pancreatic tumors. Nevertheless, specific T cells can be generated using genetic modification to express chimeric antigen receptors (CAR), which can enable T cell responses against pancreatic tumor cells. CAR T cells can be produced ex vivo and expanded in..

View full abstract

Grants

Awarded by National Health and Medical Research Council (NHMRC) of Australia


Awarded by National Breast Cancer Foundation (NBCF) of Australia


Awarded by Susan G. Komen Breast Cancer Foundation


Funding Acknowledgements

This work was supported by grants from the Peter MacCallum Cancer Center Foundation, the National Health and Medical Research Council (NHMRC) of Australia (1103352 and 1132373), the National Breast Cancer Foundation (NBCF) of Australia (IIRS-18-064) and Susan G. Komen Breast Cancer Foundation (16376637). CS was supported by a Fellowship from the NBCF. AA was supported by a University of Melbourne International Research scholarship, AO by an Australian Postgraduate Award.